F

FDI Clinical Research | San Juan, PR

Research site
(Unclaimed)
Location
998 Munoz Rivera Avenue, San Juan, Puerto Rico, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

16 of 23
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD)...

Enrolling
Type2 Diabetes
Overweight and Obesity
Drug: DD01
Drug: Placebo

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling
Non-alcoholic Steatohepatitis (NASH)
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Drug: Placebo
Drug: ALN-HSD

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obes...

Enrolling
Obese
Drug: APHD-012
Drug: APHD-012P

The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab an...

Enrolling
Carcinoma, Hepatocellular
Drug: Relatlimab
Drug: Bevacizumab

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has fail...

Enrolling
Breast Cancer Stage IV
Breast Cancer
Drug: MBQ-167

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequ...

Enrolling
Type 2 Diabetes
Drug: Orforglipron
Drug: Placebo

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+,...

Enrolling
Breast Cancer
Drug: Letrozole Tablets
Drug: Exemestane Tablets
Locations recently updated

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: NNC0174 0833 10 mg/mL
Drug: NNC0194 0499 50 mg/mL
Locations recently updated

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal...

Invitation-only
Breast Cancer
Drug: TOL2506
Drug: Letrozole tablets

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a
Drug: Docetaxel

VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adu...

Active, not recruiting
Neoplasms, Head and Neck
Metastatic Head and Neck Cancer
Combination Product: Pembrolizumab (KEYTRUDA®) and PDS0101

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

Trial conditions

Non-alcoholic Fatty Live... (9 trials)
Fatty Liver (8 trials)
Breast Cancer (4 trials)
Liver Diseases (4 trials)
Liver Cirrhosis (3 trials)
Carcinoma (2 trials)
Dyslipidemias (2 trials)
Fibrosis (2 trials)
Obesity (2 trials)
Type 2 Diabetes Mellitus (2 trials)

And 22 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems